Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
TRANZYME (NQ: TZYM)
0.5910 USD  -0.0089 (-1.48%)
Official Closing Price  /  Updated: 5:20 PM EDT, May 22, 2013  /  Add to My Watchlist      
View: Quote News
Stories about TRANZYME
 
< Previous 1 2 Next >
Tranzyme, Ocera Announce Merger Agreement
April 23, 2013
Tranzyme Pharma (NASDAQ: TZYM ) and Ocera Therapeutics, Inc. ("Ocera"), a privately held biopharmaceutical company developing novel therapeutics for liver diseases, today announced that they have... Read More
category Management , Benzinga , Global , and 5 more.
from Latest Articles from Benzinga.com
Tranzyme, Inc. (TZYM) Tops Q4 EPS by 12c
March 28, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8218730 for the full story. Read More
from StreetInsider.com News Articles
Tranzyme (TZYM) Pops on News it is Exploring 'Strategic Alternatives'
February 08, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8073715 for the full story. Read More
from StreetInsider.com News Articles
StreetInsider.com Pre-Open Movers 02/08: (ATVI) (LNKD) (AOL) Higher; (RVBD) (NUAN) (CSTR) Lower (more...)
February 08, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8073664 for the full story. Read More
from StreetInsider.com News Articles
A Peek Into The Market Before The Trading Starts
February 08, 2013
Pre-open movers US stock futures are mostly flat this morning, as investors are awaiting trade data. Futures for the Dow Jones Industrial Average dropped 1 point to 13,897.00 and S&P 500 index futures... Read More
category LH , Benzinga , ONCY , and 12 more.
from Latest Articles from Benzinga.com
CORRECTED-UPDATE 1-Tranzyme to explore sale of company
February 08, 2013
(Corrects paragraph 4 to say drug was in mid-stage trials, not late stage) Read More
category companyNews
from Reuters: Company News
Tranzyme to explore strategic options
February 08, 2013
Feb 8 (Reuters) - Drugmaker Tranzyme Inc said it will explore strategic options, including a sale, less than two months after it stopped the second mid-stage trial of its drug for stomach paralysis. Read More
category companyNews
from Reuters: Company News
Tranzyme Pharma to Explore Strategic Alternatives
February 08, 2013
Tranzyme (NASDAQ: TZYM ) announced today that its Board of Directors has made a determination to explore and evaluate strategic alternatives, including the possibility of a merger, sale, other form of... Read More
category TZYM , Management , Benzinga , and 5 more.
from Latest Articles from Benzinga.com
Tranzyme Pharma Names David Moore Chief Business Officer
January 15, 2013
Tranzyme Pharma (NASDAQ: TZYM ) today announced that David S. Moore has been named as Chief Business Officer. "Dave has provided meaningful contributions and leadership since joining Tranzyme said... Read More
category US89413J1025 , TZYM , Management , and 3 more.
from Latest Articles from Benzinga.com
A Peek Into The Market Before The Trading Starts
January 04, 2013
Pre-open movers US stock futures are mostly flat this morning, as investors are awaiting jobs data. Futures for the Dow Jones Industrial Average dropped 4 points to 13,315.00 and S&P 500 index futures... Read More
category Benzinga , Global , News , and 17 more.
from Latest Articles from Benzinga.com
Tranzyme Completes Drug Discovery Collaboration With Bristol-Myers Squibb
January 04, 2013
Tranzyme Pharma (NASDAQ: TZYM ) today announced the successful completion of its chemistry-based drug discovery collaboration with Bristol-Myers Squibb (NYSE: BMY ). As a result of the joint research... Read More
category US89413J1025 , Management , Benzinga , and 7 more.
from Latest Articles from Benzinga.com
Tranzyme Pharma (TZYM) Completes Collaboration w/ Bristol-Myers (BMY)
January 04, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=7985263 for the full story. Read More
from StreetInsider.com News Articles
Notable 52-Week Highs and Lows of the Day 12/17: (BAC) (CX) (LUV) High; (END) (LNET) (TZYM) Low
December 17, 2012
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=7953199 for the full story. Read More
from StreetInsider.com News Articles
BRIEF-Tranzyme falls 19 percent in premarket trading
December 17, 2012
NEW YORK, Dec 17 (Reuters) - Tranzyme Inc : * Shares fall 19 percent in premarket trading Read More
category companyNews
from Reuters: Company News
Tranzyme (TZYM) Halts TZP-102 Phase 2b; Cites Insufficient Efficacy
December 17, 2012
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=7951901 for the full story. Read More
from StreetInsider.com News Articles
Tranzyme (TZYM) shares halted with news pending
December 17, 2012
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=7951737 for the full story. Read More
from StreetInsider.com News Articles
Tranzyme (TZYM) CFO Eisenstadt Resigns
December 05, 2012
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=7926990 for the full story. Read More
from StreetInsider.com News Articles
Canaccord Genuity Downgrades Tranzyme (TZYM) to Hold
November 16, 2012
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=7887055 for the full story. Read More
from StreetInsider.com News Articles
Tranzyme's TZP-102 Fails Trial
November 15, 2012
Tranzyme Inc. (Nasdaq: TZYM) reported that its stomach paralysis treatment TZP-102 failed a midstage clinical trial sending the stock price plummeting $3.02 to close at $0.95.... Read More
from MarketMinute.com Stock News
Notable 52-Week Highs and Lows of the Day 11/15: (BMRN) (CALI) (HFC) High; (DRYS) (VELT) (TZYM) Low(
November 15, 2012
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=7883891 for the full story. Read More
from StreetInsider.com News Articles
Unusual 11 Mid-Day Movers 11/15: (RCON) (BXG) (CALI) Higher; (TZYM) (VELT) (DGSE) Lower
November 15, 2012
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=7883617 for the full story. Read More
from StreetInsider.com News Articles
Eurozone Falls Into Recession, Markets Drop
November 15, 2012
The Eurozone fell back into a recession in the third quarter to weigh the markets down during the midday with the Dow losing 51 points to 12,519. Nasdaq slipped 14 points to 2831. Read More
category Market News
from MarketMinute.com Market Updates
Tranzyme, Inc. (TZYM) Tops Q3 EPS by 13c
November 08, 2012
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=7860351 for the full story. Read More
from StreetInsider.com News Articles
Tranzyme (TZYM) Closes 3M Direct Offering at $3.85/Share
September 18, 2012
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=7735598 for the full story. Read More
from StreetInsider.com News Articles
Thursday’s biggest gaining and declining stocks
September 13, 2012
MarketWatch’s daily rundown of shares poised to make sizable moves in the U.S. stock market. Read More
category Computer Software , Biotechnology , Media , and 24 more.
from MarketWatch
Tranzyme Pharma (TZYM) Sells 2.6M at $3.85/Share in Direct Offering
September 13, 2012
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=7723928 for the full story. Read More
from StreetInsider.com News Articles
Canaccord Genuity Upgrades Tranzyme (TZYM) to Buy
August 13, 2012
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=7652262 for the full story. Read More
from StreetInsider.com News Articles
Tranzyme, Inc. (TZYM) Reports In-Line Q2 Loss of 23c/Share
August 09, 2012
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=7647923 for the full story. Read More
from StreetInsider.com News Articles
Cowen Starts Tranzyme (TZYM) at Outperform
July 31, 2012
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=7617565 for the full story. Read More
from StreetInsider.com News Articles
3 Biotechnology Stocks to Buy Now
July 22, 2012
 Read More
category Stocks to Buy , NASDAQ:QLTI , NASDAQ:DYAX , and 1 more.
from InvestorPlace - Latest Headlines
< Previous 1 2 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here